Top 10 Pharmaceuticals CEO

Alex Gorsky Johnson & Johnson 

Gorsky began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing, and management. In 2001, he was appointed president of Janssen, and in 2003, he was named Company Group Chairman of Johnson & Johnson's pharmaceuticals business in Europe, the Middle East and Africa.

Gorsky left Johnson & Johnson in 2004 to join the Novartis Pharmaceuticals Corporation, where he served as head of the company's pharmaceuticals business in North America. He returned to Johnson & Johnson in 2008 as company group chairman for Ethicon, Inc. In September 2009, he was appointed worldwide chairman of the Medical Devices & Diagnostics segment. In January 2011, he was named vice chairman of Johnson & Johnson's executive committee. Alex became chief executive officer on April 26, 2012, and chairman on December 28, 2012.

A longtime advocate of diversity and inclusion, Alex has been named one of the “100 Most Inspiring Leaders” by Pharma Voice. He is the Executive Sponsor of two Johnson & Johnson employee resource groups, the Women's Leadership Initiative and the Veteran's Leadership Council. Alex is also a member of the Business Council and the Business Roundtable.

Alex is a member of the board of directors of IBM, the Congressional Medal of Honor board of directors, and the board of directors of the National Academy Foundation. He was recently given the Joseph Wharton Leadership Award and the CADCA Humanitarian of the Year Award, as well as an honorary doctorate from Thomas Jefferson University in Philadelphia.

Alex holds a Bachelor of Science degree from the U.S. Military Academy at West Point, N.Y., and spent six years in the U.S. Army, finishing his military career with the rank of captain. Alex earned a Master of Business Administration degree from The Wharton School of the University of Pennsylvania in 1996.

https://en.wikipedia.org/

 

ALBERT BOURLA Pfizer

As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose: breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.

During his more than 25 years at Pfizer, Albert has built a diverse and successful career, holding a number of senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO in January 2019, Albert served as the Pfizer’s Chief Operating Officer (COO) beginning in January 2018, responsible for overseeing the Company’s commercial strategy, manufacturing, and global product development functions.

Previously, from February 2016 to December 2017, Albert served as Group President of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. In addition, he created the Patient and Health Impact Group, dedicated to developing solutions for increasing patient access, demonstrating the value of Pfizer’s medicines, and ensuring broader business model innovation.

From January 2014 to January 2016, Albert served as Group President of Pfizer’s Global Vaccines, Oncology, and Consumer Healthcare business, where he was instrumental in building a strong and competitive position in Oncology and expanding the Company’s leadership in Vaccines.

Albert was President and General Manager of Pfizer’s Established Products business from 2010-2013, leading the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio, (including legacy brands and generics.

He began his Pfizer career in 1993 in the Animal Health Division as Technical Director of Greece. He held positions of increasing responsibility within Animal Health across Europe, before moving to Pfizer’s New York Global Headquarters in 2001. From there, Albert went on to assume a succession of leadership roles within the Animal Health Division, including US Group Marketing Director (2001-2004), Vice President of Business Development and New Products Marketing (2004-2006), and Area President of Animal Health Europe, Africa and the Middle East (2006-2009). In 2009, he assumed additional responsibilities for the Asia and Pacific regions.

Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. In 2020, he was ranked as America’s top CEO in the Pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of The Partnership for New York City, a director on multiple boards – Pfizer, Inc., The Pfizer Foundation, PhRMA, and Catalyst – and a Trustee of the United States Council for International Business. In addition, Albert is a member of the Business Roundtable and the Business Council.

https://www.pfizer.com/people/leadership/executives/albert_bourla-dvm-phd

 

Severin Schwan Roche

Schwan serves as the Chief Executive Officer of F. Hoffmann-La Roche Ltd. Dr. Schwan serves as the;

He currently serves as Chief Executive Officer of Roche Group including

• Group Chief Executive Officer Roche Pharmholding B.v. since March 2008.

• Group Chief Executive Officer of Roche Holding AG at Roche Pharma AG

• Group Chief Executive Officer of Roche Diagnostics Corporation, a Diagnostics Divisions of Roche Holding Ag since January 1, 2006.

• Chief Executive Officer of Roche Diagnostics Corporation since January 1, 2006.

• Director of Roche Holdings, Inc. since April 29, 2008 and Roche Holding Ag 2013.

He previously served as the

• Head Finance & Informatics of Roche Grenzach and Member of the Executive Board of Roche Deutschland Holding GmbH from 1998 to 2000.

• Head, Global Finance & Services of Roche Diagnostics from 2000 to 2004.

• Head of Diagnostics Asia-Pacific of Roche Holding Ag from 2004 to January 1, 2006.

• Head of Global Finance & Services for the Diagnostics Division from 2000 to 2004. He served as a Director of Chugai Pharmaceutical Co. Ltd., and Genentech, Inc.

• Trainee of Corporate Finance at Roche Basel from 1993 to 1995, Head Finance & Administration at Roche Brussels from 1995 to 1998,

Dr. Schwan holds Degree in Economics from University of Innsbruck, University of York and University of Oxford Mag. rer.soc.oec. (Innsbruck, 1991) and Law from University of Innsbruck Mag. iur. (Innsbruck, 1991) and Doctorate in Law from University of Innsbruck Research studies at University Louvain, Belgium Dr. iur. (Innsbruck, 1993).

https://en.wikipedia.org/wiki/Severin_Schwan

 

Paul Hudson Sanofi

 

 

Paul Hudson joined Sanofi as CEO on September 1, 2019. 

Previously CEO of Novartis Pharmaceuticals (2016-2019), where he was a member of the Executive Committee, Paul has an expansive international career in healthcare that spans the U.S., Japan and Europe.

Prior to Novartis, he worked for AstraZeneca, where he held several increasingly senior positions and most recently carried out the roles of president, AstraZeneca United States and executive vice president, North America.

He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthélabo U.K. 

Paul holds a degree in economics from Manchester Metropolitan University in the U.K. and last year his alma mater awarded him an honorary Doctor of Business Administration for his achievements in industry. He also holds a diploma in marketing from the Chartered Institute of Marketing, also in the U.K.

“People are what drive me. I was drawn to healthcare so that I could positively impact people’s lives. As a leader, I firmly believe that making an impact starts within–how we do things, how we work with integrity, and how we empower and inspire each other to bring our best selves to work. Even on a tough day, I can be confident that our work has a positive impact on people–either by improving a patient’s life or by inspiring a colleague.” - Paul Hudson

A father of three, Paul, 51, is a hands-on dad and an ardent Manchester United football fan.

https://www.sanofi.com/en/about-us/governance/executive-committee/paul-hudson